These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36251608)

  • 1. The role of trust in the acceptance of adjuvant endocrine therapy in breast cancer patients.
    Constanze E; Uwe G; Christoph T; Kavitha D; Dominik R; Urte S; Walter B
    Psychooncology; 2022 Dec; 31(12):2122-2131. PubMed ID: 36251608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
    Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
    Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment.
    Green SMC; Hall LH; French DP; Rousseau N; Parbutt C; Walwyn R; Smith SG
    Ann Behav Med; 2023 Oct; 57(11):988-1000. PubMed ID: 37494669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dataset for a randomised factorial experiment to optimise an information leaflet for women with breast cancer.
    Green SMC; Smith SG
    NIHR Open Res; 2024; 4():32. PubMed ID: 39145099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
    Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
    JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    Farias AJ; Wu WH; Du XL
    BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients.
    Rosso R; D'Alonzo M; Bounous VE; Actis S; Cipullo I; Salerno E; Biglia N
    Curr Oncol; 2023 Jan; 30(2):1461-1472. PubMed ID: 36826073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
    Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
    Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
    Tan EH; Wong ALA; Tan CC; Wong P; Tan SH; Ang LEY; Lim SE; Chong WQ; Ho J; Lee SC; Tai BC
    Breast Cancer Res Treat; 2021 Aug; 188(3):779-788. PubMed ID: 33948777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.